Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qinjun Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1239-3820; OpenAlex author ID A5011051920. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal aden… Co-author DOI 10.1016/j.biomaterials.2025.123630↗
  2. Transcytosis-Triggering Nanoparticles for Overcoming Stromal Barriers and Reversing Immunosuppression in Pancreatic Cancer Combinatorial Therapy. Co-author DOI 10.1021/acs.nanolett.4c06372↗
  3. Intelligent micelles for on-demand drug delivery targeting extracellular matrix of pancreatic cancer. First author DOI 10.1016/j.jconrel.2024.07.058↗
  4. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Co-author DOI 10.1016/j.actbio.2023.05.047↗
  5. Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. Co-author DOI 10.1002/smll.202107712↗
  6. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121306↗
  7. Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Co-author DOI 10.1016/j.apsb.2019.11.013↗
  8. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Co-author DOI 10.1021/acs.nanolett.9b00374↗
  9. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Co-author DOI 10.1002/advs.201701070↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jiang · 7 shared papers, 2019–2026 · strength 1.35
  2. Tao Sun · 7 shared papers, 2018–2026 · strength 1.06
  3. Yu Wang · 4 shared papers, 2022–2026 · strength 0.77
  4. Hongrui Fan · 3 shared papers, 2023–2026 · strength 0.64
  5. Haolin Song · 3 shared papers, 2023–2026 · strength 0.64
  6. Chufeng Li · 2 shared papers, 2023–2024 · strength 0.50
  7. Yifan Luo · 3 shared papers, 2022–2023 · strength 0.40
  8. Shilin Zhang · 2 shared papers, 2023–2025 · strength 0.34
  9. Wenxi Zhou · 3 shared papers, 2019–2022 · strength 0.31
  10. Xinli Chen · 3 shared papers, 2019–2022 · strength 0.31
  11. Hongyi Chen · 2 shared papers, 2022–2023 · strength 0.26
  12. Qingbing Wang · 2 shared papers, 2020–2022 · strength 0.25
  13. Yu Zhou · 2 shared papers, 2020–2022 · strength 0.23
  14. Chen Liang · 2 shared papers, 2019–2022 · strength 0.20
  15. Xianjun Yu · 2 shared papers, 2019–2022 · strength 0.20
  16. Si Shi · 2 shared papers, 2019–2022 · strength 0.20
  17. Chen Jiang · 2 shared papers, 2018–2020 · strength 0.18
  18. Xiaoyi Ding · 1 shared paper, 2020 · strength 0.11
  19. Xi He · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.